On January 12, 2026, CRISPR Therapeutics AG reported on advancements in its gene editing programs, including CTX310 and CTX320, achieving reductions in triglycerides by up to 73%. The company highlighted ongoing Phase 1 trials for its autoimmune programs and promising preclinical results for diabetes treatments.